Covid-19 roundup: CDER ponders a move to virtual adcomms; conservative group urges easier access to hydroxychloroquine
It’s all hands on the virtual deck at the FDA. And the folks at CDER are considering setting up a new online approach to holding adcomm meetings going forward.
Mark Senak, who writes the Eye on FDA blog, posed a series of questions for CDER, including one on adcomms, which are being interrupted as the coronavirus pandemic spreads in the US and around the globe.
As of now, the FDA is canceling all non-essential meetings at the agency, including the adcomms, through April. But CDER does see a possible opportunity for going virtual — a big deal in an industry that relies on these meetings to keep its R&D strategy intact.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
